CHICAGO—Iso-osmolar and low-osmolar contrast agents showed similar nephrotoxicity in a study of patients with impaired renal function undergoing percutaneous coronary intervention (PCI), according to findings presented here at the American College of Cardiology annual meeting.

CHICAGO—Routine use of contrast agents for evaluating chest pain carries a risk of contrast- induced nephropathy (CIN).

WASHINGTON, D.C.—Targeted renal therapy (TRT) involving intrarenal administration of fenoldopam is safe and feasible in patients undergoing angiographic procedures, even in patients at elevated risk of suffering from contrast-induced nephropathy (CIN).

A RECENT meta-analysis supports administration of N-acetylcysteine prophylaxis to prevent contrast-induced nephropathy, especially in high-risk patients. Researchers also noted that the drug is inexpensive and readily available, and has few side effects.

PLC Systems Inc., of Franklin, Mass., has received conditional approval to begin enrollment in a pivotal trial to study the effectiveness of its RenalGuard Therapy and RenalGuard System in the prevention of contrast-induced nephropathy (CIN).

Administering N-acetylcysteine (NAC) prior to cardiac catheterization may protect patients from contrast-induced nephropathy (CIN), according to a Canadian study.

RADIOCONTRAST NEPHROPATHY (RCN) is an uncommon complication in acute stroke patients undergoing emergency CT angiography (CTA), according to Canadian researchers.

Fenoldopam delivered into the renal artery may help prevent contrast-induced nephropathy (CIN).

A large Swedish study of patients undergoing coronary procedures shows that renal failure is more likely to develop with the use of an iso-osmolar rather than low-osmolar contrast media.

SODIUM BICARBONATE may increase the risk of contrast nephropathy (CN), recent findings suggest.